Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

被引：29

作者：

Cheng, Hengmiao ^{[1
]}

Orr, Suvi T. M. ^{[1
]}

Bailey, Simon ^{[1
]}

Brooun, Alexei ^{[1
]}

Chen, Ping ^{[1
]}

Deal, Judith G. ^{[1
]}

Deng, Yali L. ^{[1
]}

Edwards, Martin P. ^{[1
]}

Gallego, Gary M. ^{[1
]}

Grodsky, Neil ^{[1
]}

Huang, Buwen ^{[1
]}

Jalaie, Mehran ^{[1
]}

Kaiser, Stephen ^{[1
]}

Kania, Robert S. ^{[1
]}

Kephart, Susan E. ^{[1
]}

Lafontaine, Jennifer ^{[1
]}

Ornelas, Martha A. ^{[1
]}

Pairish, Mason ^{[1
]}

Planken, Simon ^{[1
]}

Shen, Hong ^{[1
]}

Sutton, Scott ^{[1
]}

Zehnder, Luke ^{[1
]}

Almaden, Chau D. ^{[1
]}

Bagrodia, Shubha ^{[1
]}

Falk, Matthew D. ^{[1
]}

Gukasyan, Hovhannes J. ^{[1
]}

Ho, Caroline ^{[1
]}

Kang, Xiaolin ^{[1
]}

Kosa, Rachel E. ^{[1
]}

Liu, Ling ^{[1
]}

Spilker, Mary E. ^{[1
]}

Timofeevski, Sergei ^{[1
]}

Visswanathan, Ravi ^{[1
]}

Wang, Zhenxiong ^{[1
]}

Meng, Fanxiu ^{[2
]}

Ren, Shijian ^{[2
]}

Shao, Li ^{[2
]}

Xu, Feng ^{[2
]}

Kath, John C. ^{[1
]}

机构：

[1] Pfizer Worldwide Res & Dev, La Jolla Labs, San Diego, CA 92121 USA

[2] Wuxi AppTec, Shanghai 200131, Peoples R China

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 64卷 / 01期

关键词：

I PI3K INHIBITOR; PHASE-I; POTENT; DISCOVERY; PF-04691502; NVP-BYL719; PATHWAY;

D O I：

10.1021/acs.jmedchem.0c01652

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3K alpha is one of the most frequently mutated kinases in human cancer. A PI3K alpha-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3K alpha-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3S)-3-{[2'-amino-5-fluoro-2-(morpholin-4-yl)-4,5'-bipyrimidin-6-yl] amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1) (PF-06843195), with high PI3K alpha potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of 1.

引用

页码：644 / 661

页数：18

共 34 条

[1] Braun M.G., 2017, DISCOVERY GDC 0077 H, pMEDI
[2] Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Burger, Matthew T.
Pecchi, Sabina
Wagman, Allan
Ni, Zhi-Jie
Knapp, Mark
Hendrickson, Thomas
Atallah, Gordana
Pfister, Keith
Zhang, Yanchen
Bartulis, Sarah
Frazier, Kelly
Ng, Simon
Smith, Aaron
Verhagen, Joelle
Haznedar, Joshua
Huh, Kay
Iwanowicz, Ed
Xin, Xiaohua
Menezes, Daniel
Merritt, Hanne
Lee, Isabelle
Wiesmann, Marion
Kaufman, Susan
Crawford, Kenneth
Chin, Michael
Bussiere, Dirksen
Shoemaker, Kevin
Zaror, Isabel
Maira, Sauveur-Michel
Voliva, Charles F.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10): : 774 - 779
[3] Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors
Burger, Matthew T.
Knapp, Mark
Wagman, Allan
Ni, Zhi-Jie
Hendrickson, Thomas
Atallah, Gordana
Zhang, Yanchen
Frazier, Kelly
Verhagen, Joelle
Pfister, Keith
Ng, Simon
Smith, Aaron
Bartulis, Sarah
Merrit, Hanne
Weismann, Marion
Xin, Xiaohua
Haznedar, Joshua
Voliva, Charles F.
Iwanowicz, Ed
Pecchi, Sabina
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (01): : 34 - 38
[4] Chen P., 2015, Patent No. [WO2015155624A1, 2015155624]
[5] Chen P., 2017, Patent No. [WO2017009751A12017, 2017009751]
[6] Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design
Chen, Ping
Deng, Ya-Li
Bergqvist, Simon
Falk, Matthew D.
Liu, Wei
Timofeevski, Sergei
Brooun, Alexei
[J]. PROTEIN SCIENCE, 2014, 23 (10) : 1332 - 1340
[7] Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series
Cheng, Hengmiao
Hoffman, Jacqui E.
Le, Phuong T.
Pairish, Mason
Kania, Robert
Farrell, William
Bagrodia, Shubha
Yuan, Jing
Sun, Shaoxian
Zhang, Eric
Xiang, Cathy
Dalvie, Deepak
Rahavendran, Sadayappan V.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2787 - 2792
[8] Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
Cheng, Hengmiao
Li, Chunze
Bailey, Simon
Baxi, Sangita M.
Goulet, Lance
Guo, Lisa
Hoffman, Jacqui
Jiang, Ying
Johnson, Theodore Otto
Johnson, Ted W.
Knighton, Daniel R.
Li, John
Liu, Kevin K. -C.
Liu, Zhengyu
Marx, Matthew A.
Walls, Marlena
Wells, Peter A.
Yin, Min-Jean
Zhu, Jinjiang
Zientek, Michael
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (01): : 91 - 97
[9] Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
Cheng, Hengmiao
Bagrodia, Shubha
Bailey, Simon
Edwards, Martin
Hoffman, Jacqui
Hu, Qiyue
Kania, Robert
Knighton, Daniel R.
Marx, Matthew A.
Ninkovic, Sacha
Sun, Shaoxian
Zhang, Eric
[J]. MEDCHEMCOMM, 2010, 1 (02) : 139 - 144
[10] Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate
Coburn, SP
Mahuren, JD
Jain, M
Zubovic, Y
Wortsman, J
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) : 3951 - 3957

← 1 2 3 4 →